Drug Approval | July 10, 2023
Astellas receives FDA priority review for Zolbetuximab biologics license application
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
_256_384.jpg)
The collaboration aims to raise awareness about eye cancer, provide medical and surgical treatment support to children and supply nutritional supplements to aid in their faster recovery.
Especially valuable for young patients with multiple blocks & underlying conditions that may render angioplasty procedures with drug-eluting stents ineffective
With close to 30-40 basic screening tests available, the unit encompasses all the essential parameters typically covered in annual health check-ups
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
The company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
Collaboration to provide hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy
Introduces a line-up of brands targeting key therapeutic categories for its ophthalmology segment launc
The detailed terms in relation to the Rights Issue, including but not limited to the issue price, rights entitlement ratio, record date, timing and terms of payment will be determined in due course.
Subscribe To Our Newsletter & Stay Updated
